Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis?

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Introduction: Rheumatoid arthritis (RA) is an autoinflammatory condition characterised by painful and chronically inflamed joints. Dysregulation of the immune system leads to elevated concentrations of proinflammatory cytokines
which contribute to disease pathogenesis and neuropathic pain. The endocannabinoid receptor system (ES) is primarily found in the immune and nervous systems and is known to have potential as a therapeutic target.
Cannabidiol (CBD) is a natural compound, with few adverse effects that target the ES. CBD is a non-psychoactive phytocannabinoid that possesses analgesic, neuroprotective and anti-inflammatory effects. It could serve as an effective treatment to suppress inflammation and pain simultaneously in RA. The mechanisms that underpin the relationship between inflammation, pain signalling and the ES are poorly understood. Here, we propose a study of
the analgesic potential of CBD using in vitro and in silico methods.
Methods: A pathway map and predictive model of RA pathophysiology. was generated from primary literature using the CellDesigner and COPASI software tools. Human iPSC derived sensory neuron and neuroblastoma cell line will be
cultured and lipopolysaccharide (LPS) used to induce an inflammatory challenge. CBD will be administered at a range of doses in order to study its anti-inflammatory potential. Initially, LPS doses will be optimised in neuronal culture
experiments. Next, a series of CBD dose-response experiments will be conducted to quantify any changes in intracellular or extracellular cytokine expression by Real-Time PCR and ELISA, respectively. This data will be used to
calibrate ours in silico pathway maps and models. Ultimately this pathway model will also be used to provide preclinical evidence of CBD’s effects beyond neuronal cells.
Approach for statistical analysis: Statistical analysis package SPSS (version 24) will be used to analyse the different treatment doses in challenged and control cells. One-way ANOVA will be used initially, followed by paired student Ttest
(two tail distribution) to establish if there is a statistically significant difference between treatment and control replicates.
LanguageEnglish
Title of host publicationBrain and Neuroscience Advances
Subtitle of host publicationBNA Festival of Neuroscience 2019
ChapterNovel treatments & translational neuroscience
Volume3
DOIs
Publication statusPublished - 23 May 2019

Fingerprint

Cannabidiol
Endocannabinoids
Arthritis
Inflammation
Rheumatoid Arthritis
Computer Simulation
Lipopolysaccharides
Immune System
Pain
Neuralgia
Non-Steroidal Anti-Inflammatory Agents
Sensory Receptor Cells
Therapeutics
Neuroblastoma
Nervous System
Analgesics
Tail
Real-Time Polymerase Chain Reaction
Analysis of Variance
Anti-Inflammatory Agents

Keywords

  • Endocannnabinoid
  • Arthritis
  • Neurons
  • Inflammation

Cite this

Gibson, David ; Murray, EK ; Watterson, Steven. / Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis?. Brain and Neuroscience Advances: BNA Festival of Neuroscience 2019. Vol. 3 2019.
@inproceedings{8710f120a1da439b9920a980656cacba,
title = "Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis?",
abstract = "Introduction: Rheumatoid arthritis (RA) is an autoinflammatory condition characterised by painful and chronically inflamed joints. Dysregulation of the immune system leads to elevated concentrations of proinflammatory cytokineswhich contribute to disease pathogenesis and neuropathic pain. The endocannabinoid receptor system (ES) is primarily found in the immune and nervous systems and is known to have potential as a therapeutic target.Cannabidiol (CBD) is a natural compound, with few adverse effects that target the ES. CBD is a non-psychoactive phytocannabinoid that possesses analgesic, neuroprotective and anti-inflammatory effects. It could serve as an effective treatment to suppress inflammation and pain simultaneously in RA. The mechanisms that underpin the relationship between inflammation, pain signalling and the ES are poorly understood. Here, we propose a study ofthe analgesic potential of CBD using in vitro and in silico methods.Methods: A pathway map and predictive model of RA pathophysiology. was generated from primary literature using the CellDesigner and COPASI software tools. Human iPSC derived sensory neuron and neuroblastoma cell line will becultured and lipopolysaccharide (LPS) used to induce an inflammatory challenge. CBD will be administered at a range of doses in order to study its anti-inflammatory potential. Initially, LPS doses will be optimised in neuronal cultureexperiments. Next, a series of CBD dose-response experiments will be conducted to quantify any changes in intracellular or extracellular cytokine expression by Real-Time PCR and ELISA, respectively. This data will be used tocalibrate ours in silico pathway maps and models. Ultimately this pathway model will also be used to provide preclinical evidence of CBD’s effects beyond neuronal cells.Approach for statistical analysis: Statistical analysis package SPSS (version 24) will be used to analyse the different treatment doses in challenged and control cells. One-way ANOVA will be used initially, followed by paired student Ttest(two tail distribution) to establish if there is a statistically significant difference between treatment and control replicates.",
keywords = "Endocannnabinoid, Arthritis, Neurons, Inflammation",
author = "David Gibson and EK Murray and Steven Watterson",
year = "2019",
month = "5",
day = "23",
doi = "https://doi.org/10.1177/2398212819855490",
language = "English",
volume = "3",
booktitle = "Brain and Neuroscience Advances",

}

Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis? / Gibson, David; Murray, EK; Watterson, Steven.

Brain and Neuroscience Advances: BNA Festival of Neuroscience 2019. Vol. 3 2019. PM148 (PP).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis?

AU - Gibson, David

AU - Murray, EK

AU - Watterson, Steven

PY - 2019/5/23

Y1 - 2019/5/23

N2 - Introduction: Rheumatoid arthritis (RA) is an autoinflammatory condition characterised by painful and chronically inflamed joints. Dysregulation of the immune system leads to elevated concentrations of proinflammatory cytokineswhich contribute to disease pathogenesis and neuropathic pain. The endocannabinoid receptor system (ES) is primarily found in the immune and nervous systems and is known to have potential as a therapeutic target.Cannabidiol (CBD) is a natural compound, with few adverse effects that target the ES. CBD is a non-psychoactive phytocannabinoid that possesses analgesic, neuroprotective and anti-inflammatory effects. It could serve as an effective treatment to suppress inflammation and pain simultaneously in RA. The mechanisms that underpin the relationship between inflammation, pain signalling and the ES are poorly understood. Here, we propose a study ofthe analgesic potential of CBD using in vitro and in silico methods.Methods: A pathway map and predictive model of RA pathophysiology. was generated from primary literature using the CellDesigner and COPASI software tools. Human iPSC derived sensory neuron and neuroblastoma cell line will becultured and lipopolysaccharide (LPS) used to induce an inflammatory challenge. CBD will be administered at a range of doses in order to study its anti-inflammatory potential. Initially, LPS doses will be optimised in neuronal cultureexperiments. Next, a series of CBD dose-response experiments will be conducted to quantify any changes in intracellular or extracellular cytokine expression by Real-Time PCR and ELISA, respectively. This data will be used tocalibrate ours in silico pathway maps and models. Ultimately this pathway model will also be used to provide preclinical evidence of CBD’s effects beyond neuronal cells.Approach for statistical analysis: Statistical analysis package SPSS (version 24) will be used to analyse the different treatment doses in challenged and control cells. One-way ANOVA will be used initially, followed by paired student Ttest(two tail distribution) to establish if there is a statistically significant difference between treatment and control replicates.

AB - Introduction: Rheumatoid arthritis (RA) is an autoinflammatory condition characterised by painful and chronically inflamed joints. Dysregulation of the immune system leads to elevated concentrations of proinflammatory cytokineswhich contribute to disease pathogenesis and neuropathic pain. The endocannabinoid receptor system (ES) is primarily found in the immune and nervous systems and is known to have potential as a therapeutic target.Cannabidiol (CBD) is a natural compound, with few adverse effects that target the ES. CBD is a non-psychoactive phytocannabinoid that possesses analgesic, neuroprotective and anti-inflammatory effects. It could serve as an effective treatment to suppress inflammation and pain simultaneously in RA. The mechanisms that underpin the relationship between inflammation, pain signalling and the ES are poorly understood. Here, we propose a study ofthe analgesic potential of CBD using in vitro and in silico methods.Methods: A pathway map and predictive model of RA pathophysiology. was generated from primary literature using the CellDesigner and COPASI software tools. Human iPSC derived sensory neuron and neuroblastoma cell line will becultured and lipopolysaccharide (LPS) used to induce an inflammatory challenge. CBD will be administered at a range of doses in order to study its anti-inflammatory potential. Initially, LPS doses will be optimised in neuronal cultureexperiments. Next, a series of CBD dose-response experiments will be conducted to quantify any changes in intracellular or extracellular cytokine expression by Real-Time PCR and ELISA, respectively. This data will be used tocalibrate ours in silico pathway maps and models. Ultimately this pathway model will also be used to provide preclinical evidence of CBD’s effects beyond neuronal cells.Approach for statistical analysis: Statistical analysis package SPSS (version 24) will be used to analyse the different treatment doses in challenged and control cells. One-way ANOVA will be used initially, followed by paired student Ttest(two tail distribution) to establish if there is a statistically significant difference between treatment and control replicates.

KW - Endocannnabinoid

KW - Arthritis

KW - Neurons

KW - Inflammation

U2 - https://doi.org/10.1177/2398212819855490

DO - https://doi.org/10.1177/2398212819855490

M3 - Conference contribution

VL - 3

BT - Brain and Neuroscience Advances

ER -